PD-L1 positive BC patients with heavily pretreated have shown a manageable safety profile and meaningful clinical outcomes after treatment of durvalumab antibody (Anti-PD-L1), ORR was 46.4% and responses were ongoing in 12 of 13 responding patients (163). The gene discussed is CD274; the disease is breast cancer.